Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?
Expert Opin Pharmacother. 2024 Feb 1:1-8. doi: 10.1080/14656566.2024.2311731. Online ahead of print.ABSTRACTINTRODUCTION: Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.AREAS COVERED: Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A met...
Source: Expert Opinion on Pharmacotherapy - February 1, 2024 Category: Drugs & Pharmacology Authors: Carel Le Roux Alvin Mondoh Source Type: research
